Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Name: Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
Published: 2011
License: Public Domain

Novartis Pharmaceuticals · 2011

ClinicalTrials.gov · Datasets · License: Public Domain · 2011

Open Source ↗

psoriatic-arthritis

psoriatic arthritis, psa, acr, caspar, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Related documents